INDIANAPOLIS and YEERONGPILLY, Australia, March 14, 2024 /PRNewswire/ -- List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement to ...
Motif Bio has put together a financing package to give it the money to wrap up a Phase III trial of its antibiotic iclaprim. The agreement will see Motif Bio list on Nasdaq at the second attempt if it ...
List Biotherapeutics, a microbiome player owned by South Korean immunotherapy developer Genome & Co., unveiled plans to build a new $125 million microbiome facility in Fishers, Indiana, as part of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback